Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Gordon H Guyatt, Elie A Akl, Mark Crowther...
https://pubmed.ncbi.nlm.nih.gov/22315257/Actively Recruiting
Led by Wolfson Medical Center · Updated on 2026-09-15
62
Participants Needed
1
Research Sites
26 weeks
Total Duration
Pregnancy and the postpartum period increase the risk of venous thromboembolism VTE, especially after cesarean section. Researchers are studying and comparing the anticoagulant effects of rivaroxaban, a direct oral anticoagulant taken once daily by mouth, with enoxaparin, a low-molecular-weight heparin given by daily injection. The goal is to evaluate their laboratory effects on blood clotting parameters in women who need short-term thromboprophylaxis after elective cesarean delivery during their hospital stay. Participants are randomly assigned to receive either rivaroxaban 10 mg by mouth once daily or enoxaparin 40 mg by subcutaneous injection once daily. Treatment starts at least 12 hours after cesarean delivery and 6 hours after spinal anesthesia, continuing until hospital discharge. Blood samples are taken on postoperative day 2 before and about 3 hours after dosing to measure thrombin generation, anti-Xa activity, and drug levels. Participants also complete a satisfaction questionnaire before discharge. Safety follow-up is conducted by telephone 2 days after discharge and again at 6 weeks postpartum. During the study, participants will have blood tests to assess clotting function and drug activity, including measurements such as endogenous thrombin potential, lag time, and peak thrombin. The study tracks adverse events including bleeding and VTE from enrollment through 6 weeks postpartum. Participant satisfaction with treatment is also recorded. The total participation includes the hospital stay for treatment and follow-up calls up to 6 weeks after delivery to monitor safety and outcomes.
CONDITIONS
Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes
O
Or Marom, MD
H
Hagit Eisenberg, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Wolfson Medical Center
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From day of surgery until hospital discharge
Participants receive either rivaroxaban orally or enoxaparin by injection once daily starting at least 12 hours after cesarean delivery and 6 hours after spinal anesthesia, continuing until hospital discharge. Standard postpartum care is provided.
Daily dosing during hospital stay
Duration - Up to 6 weeks postpartum
Participants receive safety follow-up by telephone at 2 days after hospital discharge and again at 6 weeks postpartum to monitor adverse events including bleeding and blood clots.
2 telephone calls
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gordon H Guyatt, Elie A Akl, Mark Crowther...
https://pubmed.ncbi.nlm.nih.gov/22315257/Elise S Eerenberg, Pieter W Kamphuisen, Meertien K Sijpkens...
https://pubmed.ncbi.nlm.nih.gov/21900088/Ian A Greer, Catherine Nelson-Piercy
https://pubmed.ncbi.nlm.nih.gov/15811953/Paul D Stein, Russell D Hull, Fadi Kayali...
https://pubmed.ncbi.nlm.nih.gov/15234649/H Cohen, C J Doré, S Clawson...
https://pubmed.ncbi.nlm.nih.gov/25940537/Noel C Chan, John W Eikelboom, Jeffrey I Weitz
https://pubmed.ncbi.nlm.nih.gov/27126650/Stefan J Cano, Donna L Lamping, Luke Bamber...
https://pubmed.ncbi.nlm.nih.gov/23013426/Wolfson Medical Center
Lead Sponsor